Scott D. Ramsey, MD, PhD

April 16, 2015

January 29, 2014

From his vantage point as director of the Cancer Technology Assessment Group at the Fred Hutchinson Cancer Research Center in Seattle, Washington, Scott D. Ramsey, MD, PhD,sees the financial fallout of cancer care like few do.

December 28, 2013

According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.

January 19, 2012

This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.

September 21, 2010

We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.

May 01, 2010

In a survey of local-stage prostate cancer patients, preference for prostatectomy was influenced by perceptions of its efficacy and personal burden versus nonsurgical options.

May 15, 2008

Using health insurance claims, we identified common first-, second-, and third-line chemotherapy regimens for patients with lung cancer and associated utilization and costs of care.

April 01, 2006

July 01, 2004

September 25, 1998